2025-12-03 - Analysis Report
Okay, here's a report summarizing the provided information on Natera Inc (NTRA), followed by analysis.

**1. Return Rate Comparison:**

*   Ticker: NTRA
*   Company Overview: Natera Inc. is a diagnostics company focused on cell-free DNA testing.
*   NTRA Cumulative Return: 143.07%
*   VOO (S&P 500) Cumulative Return: 100.62%
*   Divergence:
    *   Current: 43.6
    *   Relative Divergence: 50.2

**Alpha, Beta Analysis Table:**

| Year      | CAGR      | MDD     | Alpha    | Beta   | Cap(B) |
|-----------|-----------|---------|----------|--------|--------|
| 2015-2017 | -10.0%    | 70.1%   | -34.0%   | -0.2   | 1.2    |
| 2016-2018 | 22.0%     | 80.0%   | 6.0%     | 0.1    | 1.9    |
| 2017-2019 | 50.0%     | 80.0%   | 28.0%    | 1.0    | 4.7    |
| 2018-2020 | 186.0%    | 80.5%   | 163.0%   | 1.1    | 13.7   |
| 2019-2021 | 96.0%     | 80.5%   | 49.0%    | 1.6    | 12.9   |
| 2020-2022 | -77.0%    | 80.5%   | -76.0%   | 0.1    | 5.5    |
| 2021-2023 | -194.0%   | 76.6%   | -195.0%  | -1.1   | 8.6    |
| 2022-2024 | 8.0%      | 76.6%   | -13.0%   | -1.2   | 21.8   |
| 2023-2025 | 170.0%    | 76.6%   | 105.0%   | 0.1    | 32.7   |

**Analysis of Return Rate and Alpha/Beta:**

*   NTRA has significantly outperformed the S&P 500 (VOO) based on cumulative return. The current divergence suggests that Natera is currently outperforming S&P 500.
*   However, the "Relative Divergence" of 50.2 indicates that while currently positive, this outperformance is not at the highest levels observed in the past.
*   The Alpha/Beta table reveals the following:
    *   **High Volatility:** NTRA has experienced significant swings in performance, as indicated by the large MDD (Maximum Drawdown) values.
    *   **Varying Alpha:** Alpha fluctuates significantly, indicating periods of both strong outperformance (positive alpha) and underperformance (negative alpha) relative to the market.
    *   **Beta Fluctuations:** Beta varies, indicating that NTRA's correlation with the market changes over time. A beta above 1 suggests that the stock is more volatile than the market. Beta below 1 indicates the stock is less volatile. Negative beta suggests the stock price tends to move in the opposite direction of the market.
    *   **Capitalization Growth:** The company's market capitalization (Cap) has generally increased over time, though it has also experienced periods of decline.

**2. Recent Stock Price Fluctuations:**

*   Current Close: 237.23
*   Last Market Data:
    *   Price: 237.16
    *   Previous Close: 234.25
    *   Change: 1.24
*   5-day SMA: 237.646
*   20-day SMA: 215.243
*   60-day SMA: 189.2125

**Analysis of Stock Price Fluctuations:**

*   The current price is slightly below the 5-day SMA, but above the 20-day and 60-day SMAs.
*   This indicates a short-term consolidation or slight pullback after a recent uptrend. The SMAs suggest an upward trend in the medium and long term. The positive change from the previous close confirms a recent upward movement.

**3. RSI, PPO and Return Analysis:**

*   Market Risk Indicator (MRI): 0.9 (High Investment Recommended)
*   RSI: 77.52
*   PPO: 0.71
*   Hybrid Signal: cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   Recent (20 days) relative divergence change = 1.7 (+): 단기상승 (Short-term increase)
*   Expected Return (%): -46.4

**Analysis of Indicators:**

*   **MRI:** The high MRI suggests the system views Natera as a relatively safe investment opportunity, despite the risks indicated by its past volatility.
*   **RSI:** An RSI of 77.52 indicates that the stock is currently overbought, which could suggest a potential pullback in the near future.
*   **PPO:** The PPO is positive, meaning that the short-term moving average is above the long-term moving average.
*   **Hybrid Signal:** This signal recommends buying the stock, indicating confidence from the model.
*   **Relative Divergence Change:** Recent increases confirm a short-term uptrend.
*   **Expected Return:** The negative expected return suggests potential underperformance compared to the S&P 500, if invested in the long term.

**4. Recent News & Significant Events (Yahoo Finance):**

*   **[2025-12-02] Morgan Stanley Raises Natera (NTRA) Price Target:** Positive news, indicating analyst confidence.
*   **[2025-09-24] Why Natera (NTRA) Stock Is Down Today:** Negative news, likely related to a specific event or broader market conditions at that time.
*   **[2025-11-30] Why Natera Remains A 'Hold' For Me:** Mixed news, suggesting a neutral stance based on specific factors.
*   **[2025-11-12] Natera (NASDAQ: NTRA) OncoEMR integration brings e-ordering to 4,500+ providers:** Positive news, indicating growth and expansion.
*   **[2025-12-01] Have Insiders Sold Natera Shares Recently?:** Potentially negative news, could indicate a lack of confidence from company insiders, but requires further investigation.
*   **[2025-11-24] $NTRA stock is up 3% today. Here's what we see in our data.:** Positive news, confirming recent upward momentum.

**4-2. Analyst Opinions:**

*   Consensus: Strong Buy
*   Mean Rating: 1.47 (~Strong Buy)
*   Opinions: 19
*   Target Price: 237.05 / 280.00 / 186.00
*   Recent Rating Changes:  (No specific changes provided)

**Analysis of Analyst Opinions:**

*   The strong buy consensus and low mean rating suggest analysts are generally optimistic about NTRA's prospects.
*   The average target price is near the current price, suggesting limited upside potential based on the average estimate. The high target price indicates some analysts are significantly more bullish. The low target price indicates there are still some analysts who are bearish.
*   The lack of specific rating changes makes it difficult to assess the recent trend in analyst sentiment.

**5. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-11-07 | -0.64 | 0.59 B$      |
| 2025-08-08 | -0.74 | 0.55 B$      |
| 2025-05-09 | -0.50 | 0.50 B$      |
| 2024-11-12 | -0.26 | 0.44 B$      |
| 2025-11-07 | -0.26 | 0.44 B$      |

**Analysis of Earnings:**

*   NTRA is currently not profitable, as evidenced by the negative EPS (Earnings Per Share) values.
*   Revenue has been generally increasing.
*   The increasing revenues, while coupled with negative EPS, suggest that the company may be focusing on growth and investment. The recent EPS appears to be becoming smaller, indicating a move toward profitability.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30 | $0.59B  | 64.91%        |
| 2025-06-30 | $0.55B  | 63.41%        |
| 2025-03-31 | $0.50B  | 63.12%        |
| 2024-12-31 | $0.48B  | 62.94%        |
| 2024-09-30 | $0.44B  | 61.79%        |

**Capital and Profitability:**

| Quarter      | Equity | ROE      |
|--------------|--------|----------|
| 2025-09-30 | $1.25B | -6.99%   |
| 2025-06-30 | $1.25B | -8.10%   |
| 2025-03-31 | $1.24B | -5.40%   |
| 2024-12-31 | $1.20B | -4.50%   |
| 2024-09-30 | $0.88B | -3.60%   |

**Analysis of Financial Information:**

*   **Revenue:** Increasing revenue trend is a positive sign, suggesting growing demand for Natera's products and services.
*   **Profit Margin:** High and increasing profit margins indicates that the company is becoming more efficient.
*   **Equity:** Consistent, and increasing equity level suggests that the company has healthy capital.
*   **ROE:** Negative ROE indicates that the company is not generating profits for its shareholders.
*   The ROE is trending upwards.

**7. Comprehensive Analysis (Summary):**

Natera (NTRA) is a high-growth, high-volatility stock with a compelling technology in the diagnostics space.

*   **Strengths:**
    *   Significant outperformance compared to the S&P 500 over certain periods.
    *   Strong revenue growth and increasing profit margins.
    *   Positive analyst sentiment with a "Strong Buy" consensus.
    *   Increasing integration and expansion, as seen in the OncoEMR news.
    *   High MRI, suggesting relatively safe investment.

*   **Weaknesses/Risks:**
    *   High volatility and significant historical drawdowns.
    *   Currently overbought (high RSI), suggesting a potential pullback.
    *   Negative EPS and ROE, indicating lack of current profitability.
    *   Potential insider selling (needs further investigation).
    *   Negative "Expected Return" indicating potential future underperformance.

*   **Overall Assessment:**

Natera presents a mixed picture. While the company shows promise with strong revenue growth and technological advancements, its lack of profitability and high volatility necessitate careful consideration. The recent price increase, analyst optimism, and hybrid signal suggest potential short-term gains. However, the overbought RSI, negative expected return, and lack of current profitability indicate long-term caution.

**Recommendation:**

A speculative buy for investors with high-risk tolerance and a belief in Natera's long-term growth potential. However, careful monitoring of earnings, insider transactions, and technical indicators is essential. Investors should be prepared for significant price swings. Due diligence on any insider selling is highly recommended before investing.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.